A phase2 study of Rituximab+THP-COP(R-THP-COP) in elderly subjects with untreated, advanced, CD20-positive, indolent B-cell Non-Hodgkin's lymphoma
Phase 2
- Conditions
- indolent B-cell lymphoma
- Registration Number
- JPRN-UMIN000002287
- Lead Sponsor
- Hematological Malignancy Clinical Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Central nervous system(CNS) NHL 2.Current or chronic hepatitis B or C infection;known seropositiviry for human immunodeficiency virus(HIV). 3.Any evidence of serious active infection 4.Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the risk associated with the subject's participation in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response rate,safty
- Secondary Outcome Measures
Name Time Method overall response rate,progression-free survival,overall survival,safty